Clinical Trials Logo

Minimal Change Disease clinical trials

View clinical trials related to Minimal Change Disease.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05441826 Terminated - Clinical trials for Focal Segmental Glomerulosclerosis

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Start date: May 3, 2022
Phase: Phase 2
Study type: Interventional

Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid therapy.

NCT ID: NCT04235621 Terminated - Clinical trials for Diabetic Nephropathies

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

Start date: December 20, 2019
Phase:
Study type: Observational

This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests will be conducted, and urine will be collected approximately every 2 weeks for 8 weeks. Patients may participate in Part 1, Part 2, or both, and will be followed for up to 1 year consisting of data collection from the patient's medical records and home collection of urine samples every 4 months.